PVR and neoplasm: Recently, it has been described the expression of TIGIT in different murine tumor cell lines (colon cancer, breast cancer, melanoma and lung carcinoma) and human colorectal cancer that delivers inhibitory signals to CD8+ T cells and NK cells by engaging with CD155 expressed on these immune cells.